Summary Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover study of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was performed in patients receiving BCNU for relapsed glioblastoma, to investigate whether the resulting haematological toxicity profile could be modified by rhGM-CSF. Adequate data for analysis were obtained in 13 patients. Following BCNU, the nadir neutrophil count was higher in 12 out of 13 patients during the rhGM-CSFprotected cycles compared with the unprotected cycles. The median nadir was also significantly higher (1.79, CI 0.76-3.52, P< 0.005). Five episodes of neutropenia ( < 2 x 109 1-) occurred during the unprotected cycles compared with none in the rhGM-CSF-protected cycles (P = 0.076). There was no evidence of any effect on platelets. This result shows that the haematological toxicity profile following therapeutic doses of BCNU can be modified. It suggests that rhGM-CSF and other growth factors should be investigated for clinical efficacy in chemotherapy using nitrosoureas.
In addition to the difficulties that attend the chemotherapy of solid tumours in other sites, the treatment of malignant brain tumours (MBTs) is further complicated by access problems owing to the presence of the blood-brain barrier (BBB). The most successful agents in terms of response and palliation in relapse as well as prolongation of survival in primary treatment are the nitrosoureas, which readily gain access to the central nervous system. However, their protracted haematological toxicity profile limits scheduling possibilities (Martindale, 1992) . In tumours such as malignant glioma which have rapid proliferation kinetics (Hoshino et al., 1992) , this is a serious disadvantage. A means of increasing the schedule frequency for these drugs could have important implications. The availability of haemopoietic colony-stimulating factors raises the possibility of modifying the haematological toxicity profile for the nitrosoureas and hence of accelerating the scheduling frequency.
In 1988 McElwain presented the rationale for the intensification of the treatment of glioma with nitrosourea (Mbidde et al., 1988) . His study of high-dose BCNU with bone marrow rescue produced modestly encouraging results which were marred by non-haematological toxicity. While this may always limit the use of these drugs in ultrahigh dose, the rationale for limited dose escalation remains. It therefore seems appropriate also to investigate colonystimulating factors for their potential to allow dose escalation.
Recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) is a haematopoietic growth factor which has been shown in vitro to affect the development and function of progenitor granulocyte, eosinophil and macrophage lineages. It facilitates myeloid progenitor cell division and modulates the function of mature neutrophils and macrophages to promote microbial killing. Comprehensive reviews of the preclinical investigation of rhGM-CSF are available (Dunlop et al., 1991; Lieschke et al., 1992a) . There have also been reports of a beneficial effect on platelet toxicity (Brandt et al., 1988; Steward et al., 1990) . Since the first combination of rhGM-CSF with a chemotherapy regimen was reported by Antman et al. (1988) , a number of phase II studies have been reported using different regimens. These have been reviewed by Lieschke et al. (1992b) . To Patients were allocated to receive rhGM-CSF on either cycle 1 or cycle 2 at random, using random permuted blocks of size 4.
After the study was completed a cursory examination of the blood profiles revealed that the timing of the white count nadir was not at all distinct for the majority of patients. This end point was therefore not amenable to statistical analysis. The analysis presented here concentrates on the secondary end points -'nadirs' and 'values in week 6' for neutrophils, white count and platelets.
The only blood counts considered for the main statistical analysis were those in which there was a corresponding count taken within 2 days (in terms of time from when BCNU was given) in the other cycle. The 'nadirs' used are the minimum of such values found on each cycle. The 'values in week 6' consist of the latest recorded count on either cycle (between day 36 and 42 of the cycle) and a corresponding count on the other cycle taken within 2 days of it.
The analysis of all counts uses the non-parametric technique described by Jones & Kenward (1989, pp. 51-59) . For the analysis of the incidence of very low counts (for neutrophils and white cells) the adjusted version of Prescott's test was used (Jones & Kenward, 1989, pp. 98-100 Thirteen patients were included in the efficacy analysis. Their details are shown in Table I . All completed two cycles of BCNU without dose modifications of any kind. There were no delays in treatment because of neutropenia following cycles with or without rhGM-CSF. The median number of days for which patients included in the efficacy analysis received rhGM-CSF was 26 days (range 19-39).
Haematological effects A typical profile of a blood count during treatment is seen in Figure 1 . rhGM-CSF was given for 23 days. Neutrophil nadirs in both cycles occurred at a similar time but were not as severe in the cycle with rhGM-CSF.
The median blood counts for each treatment group and each cycle are presented in Table II . In Table III the estimated effects of rhGM-CSF and cycle on the median counts are given.
For neutrophil nadirs there was no discernible cycle effect, but the effect of rhGM-CSF in ameliorating the nadir neutrophil count was highly significant (P=0.005). The nadir count was higher for 12 of the 13 patients in the rhGM-CSF cycle than in the cycle without rhGM-CSF. Tables II and III show similar figures for the total white cell count. There is again a significant rhGM-CSF effect in raising the nadir, but this time there is a significant cycle effect also. This implies a cumulative effect of the BCNU on the non-neutrophil leucocyte component. Table III shows differences in median neutrophil values in week 6 for cycles with and without rhGM-CSF. Again there is a significant influence of rhGM-CSF, which produces higher levels of neutrophils (P = 0.003), while there is no significant cycle effect (P = 0.72).
Altogether there were five neutrophil nadirs lower than 2 x 109 1'. All occurred during courses unprotected by rhGM-CSF. This reduction in the incidence of neutrophil nadirs less than 2 did not quite reach conventional levels of statistical significance (P = 0.076) but, nevertheless, taken with the other evidence, is indicative of a protective effect of rhGM-CSF.
An examination of plots such as Figure 1 revealed that for many patients the exact timing of the neutrophil nadir was indistinct. However, given these difficulties, it still did not appear that the effect of rhGM-CSF was to alter the timing of the neutrophil nadir.
Table III also shows differences in the median of the platelet nadirs. rhGM-CSF had no effect on these (P = 0.62), although there was a strong cycle effect (P = 0.038), showing the cumulative toxic effect of the nitrosoureas on this compartment of the myeloproliferative system. This is also emphasised in the 6 week levels, which are included in the from the formation of DNA cross-linkage and the depletion of glutathione, but it appears from in vitro studies that they do not share cross-resistance with classical alkylating agents. Their principal toxic effect is on the bone marrow, which leads to clinically relevant neutropenia and thrombocytopenia. While thrombocytopenia is more common, neutropenia may be profound and dose-limiting (Martindale, 1992) . Both phenomena occur later than with most commonly used cytotoxic agents. Nadirs typically occur at 4-6 weeks but may sometimes persist until week 7 or 8. This feature limits the usefulness of this class of drug since the 6 week delay which is usually necessary between cycles allows regrowth of tumours with rapid cell proliferation kinetics. If a method could be devised for safely increasing the frequency with which these drugs could be delivered their value in treating malignant tumours could be considerably enhanced.
The nitrosoureas remain the most useful class of drug in the treatment of malignant glioma. Their non-ionised highly lipid-soluble nature allows them ready access to the brain. BCNU is the most studied drug in this disease and is still generally thought to be the most effective, although modifications to the basic structure may produce some advantages (Gregor et al., 1992) . Response occurs in approximately 30% of patients with recurrent disease, and there is a modest prolongation of survival when used in the adjuvant setting (Stenning et al., 1987) . It is recognised that the therapeutic index for BCNU is low (Kornblith et al., 1988) , being limited in the first instance by marrow toxicity. Attempts have been made to improve this by using ultrahigh dose BCNU with bone marrow rescue (Hochberg et al., 1981; Mbidde et al., 1988) . While a possible improvement in survival was observed, justifying the rationale of the approach, non-haematological toxicity remained a problem. An alternative and potentially less toxic approach might be to employ a more modest dose intensification scheme either by accelerating the frequency of the drug or by dose escalation under colony-stimulating factor cover.
Our results show that the neutrophil toxicity of BCNU, at least in the first two cycles, is indeed reduced by rhGM-CSF. The nadir neutrophil count was higher for 12 out of 13 patients in the protected cycle compared with the unprotected cycle. The resulting median nadir was significantly higher in the cycles with rhGM-CSF. There was no suggestion of a cycle effect, which was not true for either platelets or the total white count. Thus, if neutropenia were thought to be the limiting toxicity it may be possible to increase the administered dose safely and over a number of courses of BCNU.
No alteration could be observed in the timing of the neutrophil nadir, although it must be said that the nadirs in the rhGM-CSF cycles were frequently indistinct or even nondiscernible. However, no episodes of grade 1 neutropenia were seen during the protected courses compared with five during courses not protected by rhGM-CSF. Hence, if neutrophil toxicity were normally dose limiting it still might be possible to increase the drug cycle time using these same doses. The therapeutic implications of this for malignant glioma are considerable since it might allow two or more cycles of drug to be given between surgery and radiotherapy at a time when the proliferative potential of the tumour is high. Radiotherapy remains the first-line treatment of this condition but must be delayed several weeks following surgery to allow wound healing and treatment planning. An effective means of treatment at this stage could possibly enhance the value of radiotherapy.
Although rhGM-CSF, when infused or given subcutaneously, undoubtedly causes a rise in neutrophils and eosinophils and less profoundly in monocytes and lymphocytes, its influence on platelets is less clear. Edmondson et al. (1989) have shown that twice-daily subcutaneous GM-CSF improves the platelet counts of patients being treated with carboplatin and cyclophosphamide, and Steward et al. (1990) have suggested benefit after treatment with high-dose melphalan. However, we saw no improvement in platelet count after treatment with BCNU and this toxicity would preclude any nitrosourea dose escalation with this colonystimulating factor alone.
Toxicity seen with rhGM-CSF was similar to that reported elsewhere (Steward et al., 1989) and predominantly involved skin rashes. No cardiac toxicity was noted and bone pain and headache at this dose were infrequent and mild.
No serious infections were seen in either group of patients, and it seems that at this dose BCNU is a safe drug even without rhGM-CSF protection. This would give further encouragement to consider dose or frequency escalation.
We conclude therefore that the neutrophil toxicity profile of BCNU can be favourably affected by rhGM-CSF. This could allow dose intensity escalation, although platelet toxicity may then become a limiting factor. With this in mind a similar study using interleukin 6 (IL-6) in combination with BCNU is under way. Future studies of such combinations of growth factors will need to include an assessment of potential protection over a full treatment course because of the possibility of cumulative toxicity extending beyond the first two cycles.
